Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.

@article{Trebst2006PromotionOR,
  title={Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.},
  author={Corinna Trebst and Martin Stangel},
  journal={Current pharmaceutical design},
  year={2006},
  volume={12 2},
  pages={
          241-9
        }
}
During the last decade immunomodulatory treatments have been shown to influence the natural course of multiple sclerosis (MS). However, demyelination in the central nervous system (CNS) still occurs and repair mechanisms are incomplete leading to neurological deficits. Currently, there is no therapy available to promote remyelination and thus enhance repair mechanisms. Both immunoglobulins directed against spinal cord homogenate and polyclonal immunoglobulins for intravenous use (IVIg) have… CONTINUE READING